8-KEarnings & ResultsFinancial EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 19, 2005)

Filed October 19, 2005For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on October 19, 2005, primarily to report its third-quarter 2005 financial results and a restructuring plan. The company announced its operational results, utilizing non-GAAP financial measures to provide investors with a view of ongoing business performance, excluding items like merger-related costs and restructuring charges. Management believes these non-GAAP measures are valuable for evaluating operational effectiveness, though investors are advised to consider them alongside GAAP measures. Furthermore, Abbott confirmed a previously anticipated plan to realign its global manufacturing operations. This restructuring, expected to be substantially completed by the end of 2007, will impact selected global pharmaceutical manufacturing operations and involve staffing reductions. The company anticipates incurring approximately $200 million in after-tax restructuring charges, a portion of which was recognized in the third quarter. These charges comprise employee termination costs, impairment and accelerated depreciation of assets, and other exit costs.

Key Highlights

  • 1Abbott Laboratories reported its third-quarter 2005 results of operations.
  • 2The company utilizes non-GAAP financial measures (e.g., earnings excluding certain items) to present ongoing business performance, alongside GAAP measures.
  • 3Abbott confirmed a global manufacturing operations realignment plan.
  • 4The realignment will affect selected global pharmaceutical manufacturing operations and involve staffing reductions.
  • 5The restructuring is expected to be substantially completed by the end of 2007.
  • 6Abbott anticipates approximately $200 million in after-tax restructuring charges associated with this plan.
  • 7Restructuring charges include employee termination costs, asset impairment/depreciation, and other exit costs.

Frequently Asked Questions

This 8-K filing by Abbott Laboratories serves two main purposes: to report the company's third-quarter 2005 financial results and to disclose details about a significant restructuring plan for its global manufacturing operations.

Abbott uses non-GAAP financial measures, such as earnings from continuing operations excluding certain specified items, to provide investors with a clearer view of the company's ongoing business performance. These measures exclude unusual or unpredictable items like merger costs, restructuring charges, and litigation, which management believes helps investors better evaluate operational effectiveness. However, Abbott advises investors to consider these non-GAAP measures in addition to, and not as a substitute for, GAAP financial measures.

Abbott is realigning its global manufacturing operations to reduce costs, which will involve staffing reductions in certain areas. The plan is expected to be substantially completed by the end of 2007 and will impact selected global pharmaceutical manufacturing operations. The company anticipates incurring approximately $200 million in after-tax restructuring charges, including employee termination costs ($45 million), asset impairment and accelerated depreciation ($90 million, non-cash), and other exit costs ($65 million).

Affected employees were notified of the restructuring plan on October 19, 2005, the same day this 8-K filing was made public.